$163 Million is the total value of Tamarack Advisers, LP's 33 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NUVA | New | NUVASIVE INCequity | $8,874,000 | – | 160,000 | +100.0% | 5.43% | – |
QDEL | New | QUIDEL CORPequity | $6,579,000 | – | 150,000 | +100.0% | 4.03% | – |
CVS | New | CVS HEALTH CORPequity | $6,099,000 | – | 75,000 | +100.0% | 3.73% | – |
ATRC | New | ATRICURE INCequity | $2,237,000 | – | 100,000 | +100.0% | 1.37% | – |
EVH | New | EVOLENT HEALTH INC - Aequity | $1,335,000 | – | 75,000 | +100.0% | 0.82% | – |
SIEN | New | SIENTRA INCequity | $924,000 | – | 60,000 | +100.0% | 0.57% | – |
New | ESRX US 01/19/18 C60call | $510,000 | – | 1,000 | +100.0% | 0.31% | – | |
New | HCA US 01/19/18 C80call | $454,000 | – | 1,121 | +100.0% | 0.28% | – | |
New | HSIC US 01/19/18 P87.5put | $286,000 | – | 400 | +100.0% | 0.18% | – | |
New | SYK US 11/17/17 P145put | $193,000 | – | 350 | +100.0% | 0.12% | – | |
New | SHPG US 01/19/18 C185call | $94,000 | – | 750 | +100.0% | 0.06% | – | |
New | BAX US 10/20/17 P62.5put | $18,000 | – | 250 | +100.0% | 0.01% | – | |
New | ALR US 10/20/17 P50put | $15,000 | – | 1,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERADIGM ORD | 32 | Q3 2023 | 13.9% |
STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
ATRICURE ORD | 29 | Q3 2023 | 7.6% |
PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
HOLOGIC INC | 17 | Q1 2022 | 6.5% |
SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
Correvio Pharma Corp. | February 15, 2019 | ? | ? |
Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-16 |
13F-HR | 2023-08-10 |
SC 13D/A | 2023-06-22 |
13F-HR | 2023-05-11 |
13F-HR | 2023-02-13 |
SC 13D/A | 2022-12-01 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.